ASGCT 2020
  • Registration
    • COVID-19
    • FAQs
    • Media
  • Abstracts
    • Call for Abstracts
    • Submission and Presentation Information
    • Award Recipients
    • Abstract Topic Categories
    • Embargo Policy
    • Awards and Incentives
    • Disclosure Slide Template
  • Hotel & Travel
  • Program
    • Pre-Meeting Workshops
    • Schedule & App
    • Plenary Speakers
    • Disclosure Slide Template
    • PDF Program
  • Exhibitors & Sponsors
    • Exhibitor, Sponsor, and Advertiser Prospectus
      • PDF
    • Current Exhibitors & Sponsors
    • COVID-19
  • Media
    • Registration
    • Media Policy
  • Contact Us
  • www.asgct.org
Quick Links
  • ASGCT.org

Connect with us

ASGCT 2020

  • Registration
    • COVID-19
    • FAQs
    • Media
  • Abstracts
    • Call for Abstracts
    • Submission and Presentation Information
    • Award Recipients
    • Abstract Topic Categories
    • Embargo Policy
    • Awards and Incentives
    • Disclosure Slide Template
  • Hotel & Travel
  • Program
    • Pre-Meeting Workshops
    • Schedule & App
    • Plenary Speakers
    • Disclosure Slide Template
    • PDF Program
  • Exhibitors & Sponsors
    • Exhibitor, Sponsor, and Advertiser Prospectus
    • Current Exhibitors & Sponsors
    • COVID-19
  • Media
    • Registration
    • Media Policy
  • Contact Us
  • www.asgct.org
×

Abstract Topic Categories

When submitting an abstract, authors will select one first choice topic and one second choice topic from the list below that best describes their abstract.

A1 – RNA Virus Vectors
A2 – AAV Vectors – Virology and Vectorology
A3 – AAV Vectors – Preclinical and Proof-of-Concept Studies

A4 – AAV Vectors – Clinical Studies
B – Gene Targeting and Gene Correction (Basic development of novel technologies for genome editing, with or without site-specific endonuclease. Gene targeting projects focused on specific disease applications are strongly encouraged to submit abstracts to the suitable tissue/disease related category.)
C – Oligonucleotide Therapeutics (siRNAs, aptamers, antagomirs, miRNAs, shRNA, antisense, and splice switching oligos, plasmids)
D – Synthetic/Molecular Conjugates and Physical Methods for Delivery of Gene Therapeutics (Including exosomes)
E1 – Metabolic, Storage, Endocrine, Liver and Gastrointestinal Diseases
E2 – Cardiovascular and Pulmonary Diseases

E3 – Neurologic Diseases (Including Ophthalmic and Auditory Diseases)
E4 – Musculo-skeletal Diseases
E5 – Cancer – Immunotherapy, Cancer Vaccines
E6 – Cancer – Oncolytic Viruses
E7 – Cancer – Targeted Gene and Cell Therapy
E8 – Hematologic and Immunologic Diseases

F – Immunological Aspects of Gene Therapy and Vaccines (Includes host responses, therapy/prevention of infectious diseases; excludes cancer immunotherapy and cancer vaccines)
G – Cell Therapies (Includes development of somatic, embryonic and induced pluripotent stem cells or other therapeutic cell populations, and issues related to cell expansion or processing)
H1 – Vector and Cell Engineering, Production or Manufacturing
H2 – Pharmacology/Toxicology Studies or Assay Development

Important Dates

Abstract Notifications Sent
April 6, 2020

Abstracts Released
April 28, 2020

23rd ASGCT Annual Meeting
May 12 – 15, 2020

Download the #ASGCT20 App

Use the ASGCT app on your mobile device to build your schedule, read the abstracts (released on April 28), and guide your way through the Hynes Convention Center.

Hynes Convention Center
900 Boylston St.
Boston, MA 02115


Sponsors

Diamond

ASGCT AM20

Platinum

ASGCT AM20
ASGCT AM20
ASGCT AM20
ASGCT AM20

View Exhibitors & Sponsors »

American Society of Gene & Cell Therapy

Office

American Society of Gene & Cell Therapy
555 East Wells Street, Suite 1100
Milwaukee, WI 53202-3823 USA
Tel: 414.278.1341
Fax: 414.276.3349
Email: info@asgct.org

Quick Links

  • ASGCT 2020 Homepage
  • Registration
  • Abstracts
  • Hotel & Travel
  • Program
  • Exhibitors & Sponsors
  • Media
  • Contact ASGCT

Follow Us

© 2020 American Society of Gene & Cell Therapy. All rights reserved.